|
Jan 31
|
Novartis Pares Gains As Its Bread-And-Butter Drug Faces Looming Competition
|
|
Jan 31
|
Novartis Ag (NVS) Q4 2024 Earnings Call Transcript
|
|
Jan 31
|
Novartis (NVS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
|
|
Jan 31
|
Health Care Roundup: Market Talk
|
|
Jan 31
|
Novartis sets ‘ambitious’ target; Skyrizi, Rinvoq sales climb
|
|
Jan 31
|
Novartis Q4 Earnings: Revenue And EPS Beat, CEO Dismisses Entresto Patent Expiration Worries
|
|
Jan 31
|
Trending tickers: Apple, Intel, Novartis, Shell, Smiths Group
|
|
Jan 31
|
Novartis: Q4 Earnings Snapshot
|
|
Jan 31
|
Novartis Expects Further Profit, Sales Growth Despite Competition Threat
|
|
Jan 31
|
Novartis beats Q4 earnings consensus as drug sales surge
|
|
Jan 31
|
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024
|
|
Jan 31
|
Chevron earnings, December PCE, FedSpeak: What to Watch
|
|
Jan 28
|
Novartis to Report Q4 Earnings: What's in the Offing?
|
|
Jan 3
|
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More
|
|
Jan 3
|
Positive data could expand use of Novartis’ gene therapy for SMA
|
|
Dec 31
|
Novartis' Gene Therapy Meets Primary Endpoint in SMA Study
|
|
Dec 31
|
Here's Why Novartis (NVS) is a Strong Growth Stock
|
|
Dec 31
|
Novartis’ Gene Therapy Shows Promise in Treating SMA
|
|
Dec 31
|
Novartis’ Phase III spinal muscular atrophy therapy trial meets primary endpoint
|
|
Dec 30
|
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
|